Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study.
add-on therapy
hepatocellular carcinoma
propensity analysis
sorafenib
transarterial chemoembolization
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Jul 2019
15 Jul 2019
Historique:
received:
17
06
2019
revised:
06
07
2019
accepted:
12
07
2019
entrez:
18
7
2019
pubmed:
18
7
2019
medline:
18
7
2019
Statut:
epublish
Résumé
We hypothesized that sorafenib plus transarterial chemoembolization (TACE) would confer survival benefits over sorafenib alone for advanced hepatocellular carcinoma (aHCC). We investigated this while using the population-based All-Cancer Dataset to assemble a cohort (
Identifiants
pubmed: 31311148
pii: cancers11070985
doi: 10.3390/cancers11070985
pmc: PMC6679028
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 106-2221-E-468-019
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 106-2632-E-468-002
Références
Am J Gastroenterol. 2008 Apr;103(4):914-21
pubmed: 18177453
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Cancer Sci. 2008 Oct;99(10):2037-44
pubmed: 19016764
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Oncologist. 2010;15(11):1198-204
pubmed: 21036880
Am J Surg. 2010 Nov;200(5):659-64
pubmed: 21056149
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e833-8
pubmed: 21570205
Aliment Pharmacol Ther. 2011 Jul;34(2):205-13
pubmed: 21605146
J Clin Oncol. 2011 Oct 20;29(30):3960-7
pubmed: 21911714
J Dig Dis. 2013 Apr;14(4):181-90
pubmed: 23324079
Ann Oncol. 2013 Jul;24(7):1786-92
pubmed: 23508822
J Clin Epidemiol. 2013 Aug;66(8 Suppl):S138-44
pubmed: 23849148
Radiology. 2013 Nov;269(2):603-11
pubmed: 23864102
Gastroenterology. 2014 Jul;147(1):143-151.e5
pubmed: 24704525
Radiology. 2014 Jul;272(1):284-93
pubmed: 24708192
Biometrics. 2014 Sep;70(3):619-28
pubmed: 24888739
BMC Cancer. 2014 Aug 29;14:634
pubmed: 25174953
Int J Gynecol Cancer. 2015 Jul;25(6):968-76
pubmed: 25893280
Radiology. 2015 Nov;277(2):594-603
pubmed: 26069923
Radiology. 2016 May;279(2):630-40
pubmed: 26744927
Cancer Sci. 2016 Apr;107(4):507-13
pubmed: 26752068
BMC Cancer. 2016 Feb 04;16:57
pubmed: 26846920
J Hematol Oncol. 2016 Mar 08;9:20
pubmed: 26957312
Liver Cancer. 2016 Feb;5(1):37-46
pubmed: 26989658
BMC Gastroenterol. 2016 Apr 27;16:50
pubmed: 27117280
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Int J Oncol. 2017 Jan;50(1):297-309
pubmed: 27959383
N Engl J Med. 2016 Dec 8;375(23):2293-2297
pubmed: 27959688
Clin Transl Oncol. 2017 Jul;19(7):891-897
pubmed: 28160206
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376195
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575
pubmed: 28648803
Eur J Epidemiol. 2017 Nov;32(11):1019-1031
pubmed: 28864947
Oncotarget. 2017 Jun 29;8(57):97613-97622
pubmed: 29228637
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Clin Pharmacol Ther. 2018 Aug;104(2):239-241
pubmed: 29733448
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Hepatol. 2019 Apr;70(4):684-691
pubmed: 30529387